Two other drugs, trastuzumab emtansine and brentuximab vedotin, are both in late clinical trials, and the latter has been granted accelerated approval for the treatment of refractory Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.
Outros dous fármacos, trastuzumab emtansine e brentuximab vedotin, están ambos en ensaios clínicos en fase final, e o segundo deles recibiu unha "aprobación acelerada" para o tratamento do linfoma de Hodgkin refractario e o linfoma de células grandes anaplástico sistémico.